查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1813889

美國遺傳性癌症檢測市場規模、佔有率和趨勢分析報告：按癌症類型、技術、檢測類型、最終用途和細分市場預測，2025-2033 年

U.S. Hereditary Cancer Testing Market Size, Share & Trends Analysis Report By Cancer, By Technology, By Test Type, By End-use, And Segment Forecasts, 2025 to 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

市場規模與趨勢：

美國遺傳性癌症檢測市場規模預計在 2024 年達到 19.3 億美元，預計到 2033 年將達到 57.6 億美元，2025 年至 2033 年的複合年成長率為 13.32%。

美國遺傳性癌症檢測市場的成長動力源自於人們對遺傳性癌症風險日益成長的認知，5-10% 的癌症與生殖系突變有關。 NCCN 和 ACOG 指南篩檢的採用率不斷提高，加上 FDA 專家小組的批准，正在提升臨床醫生的信心並擴大支付方覆蓋範圍。 DNA/RNA 整合定序、數位篩檢工具以及生殖系和體細胞分析等技術進步正在擴大臨床效用。加強夥伴關係、開展病患教育計畫以及提供保險支持，正在進一步加速基因檢測的可及性，並將基因檢測定位為精準腫瘤學的基石。

在美國，5–10% 的癌症與癌症易感基因的遺傳突變有關。這些遺傳突變透過家族遺傳，增加了乳癌、卵巢、大腸癌和攝護腺癌等癌症的風險。雖然大多數乳癌病例（估計有 27 萬名女性、2,000 名男性和 20,000 例卵巢癌病例）每年發生，但這些病例是偶發的，但很大一部分是遺傳性的。這凸顯了基因檢測作為早期發現和預防性醫療保健工具的重要性。美國國家綜合癌症網路 (NCCN) 已製定指南，主要根據個人和家族癌症史來識別最有可能攜帶突變的個體。然而，儘管這些指南很有力度，但基因檢測歷來未充分利用，部分原因是各實驗室的解釋不一致以及患者獲得檢測的機會有限。

目錄

第1章調查方法與範圍

第2章執行摘要

第3章美國遺傳性癌症檢測市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/輔助市場前景。
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 美國遺傳性癌症檢測市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析

第4章美國遺傳性癌症檢測市場：癌症估計與趨勢分析

  • 細分儀表板
  • 美國遺傳性癌症檢測市場：癌症變異分析
  • 美國遺傳性癌症檢測市場規模與趨勢分析（按癌症類型，2021-2033 年）
  • 2021-2033年美國遺傳性癌症檢測市場收益估計與預測
  • 肺癌
  • 乳癌
  • 大腸直腸癌
  • 子宮頸癌
  • 卵巢癌
  • 攝護腺癌
  • 胃癌
  • 黑色素瘤
  • 肉瘤
  • 子宮癌
  • 胰臟癌
  • 其他

第5章美國遺傳性癌症檢測市場：技術評估與趨勢分析

  • 2024年及2033年技術市場佔有率
  • 細分儀表板
  • 美國遺傳性癌症檢測市場：技術展望
  • 2021年至2033年市場規模、預測與趨勢分析
  • 細胞遺傳學
  • 生化
  • 分子檢測

第6章美國遺傳性癌症檢測市場：檢測類型估計與趨勢分析

  • 2024 年和 2033 年測試類型市場佔有率
  • 細分儀表板
  • 按測試類型分類的市場前景
  • 2021年至2033年市場規模、預測與趨勢分析
  • 預測測試
  • 診斷測試

第7章美國遺傳性癌症檢測市場：最終用途估計與趨勢分析

  • 2024年和2033年的最終用途市場佔有率
  • 細分儀表板
  • 按最終用途分類的市場前景
  • 2021年至2033年市場規模、預測與趨勢分析
  • 診斷中心
  • 醫院
  • 診所

第8章 競爭態勢

  • 主要市場參與企業的近期趨勢和影響分析
  • 公司/競爭對手分類
  • 供應商格局
    • 主要經銷商和通路合作夥伴名單
    • 主要客戶
    • 2024年主要企業市場占有率分析
    • Myriad Genetics, Inc.
    • Invitae Corporation
    • Bio-Rad Laboratories
    • CSL Ltd
    • Qiagen NV
    • Danaher Corporation
    • Thermo Fisher Scientific
    • Abbott Laboratories
    • EUROFINS SCIENTIFIC
    • F. HOFFMANN-LA ROCHE LTD
    • Illumina, Inc.
Product Code: GVR-4-68040-721-8

Market Size & Trends:

The U.S. hereditary cancer testing market was estimated at USD 1.93 billion in 2024 and is projected to reach USD 5.76 billion by 2033, growing at a CAGR of 13.32% from 2025 to 2033. The U.S. hereditary cancer testing market is driven by growing awareness of inherited cancer risks, with 5-10% of cancers linked to germline mutations. Rising adoption of guideline-based screening from NCCN and ACOG, coupled with FDA authorization of panels, is boosting clinician confidence and payer coverage. Technological advancements such as integration of DNA/RNA sequencing, digital screening tools, and combined germline-somatic profiling are expanding clinical utility. Increasing partnerships, patient education initiatives, and insurance support are further accelerating access, positioning hereditary testing as a cornerstone of precision oncology.

In the United States, between five and ten percent of all cancers are associated with inherited mutations in cancer predisposition genes. These hereditary mutations, passed down through families, increase the risk of developing cancers such as breast, ovarian, colorectal, prostate, and others. While most of the estimated 270,000 annual breast cancer cases among women, 2,000 among men, and 20,000 ovarian cancer cases occur sporadically, a notable proportion is hereditary. This underscores the importance of genetic testing as a tool for both early detection and preventive healthcare. The National Comprehensive Cancer Network (NCCN) has established guidelines to identify individuals most likely to carry mutations, primarily based on personal and family cancer histories. Yet, despite the strength of these guidelines, hereditary testing has historically been underutilized, partly because of inconsistent interpretation across laboratories and limited patient access.

U.S. Hereditary Cancer Testing Market Report Segmentation

This report forecasts revenue growth at, country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For the purpose of this study, Grand View Research has segmented the hereditary cancer testing market report on the basis of test type, technology, cancer, andend-use:

  • Cancer Outlook (Revenue, USD Million, 2021 - 2033)
  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Cervical Cancer
  • Ovarian Cancer
  • Prostate Cancer
  • Stomach/Gastric Cancer
  • Melanoma
  • Sarcoma
  • Uterine Cancer
  • Pancreatic Cancer
  • Others
  • Technology Outlook (Revenue, USD Million, 2021 - 2033)
  • Cytogenetic
  • Biochemical
  • Molecular Testing
  • Test Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Predictive Testing
  • Diagnostic Testing
  • End-use Outlook (Revenue, USD Million, 2021 - 2033)
  • Diagnostic Centers
  • Hospitals
  • Clinics

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Cancer
    • 1.2.2. Technology
    • 1.2.3. Regional scope
    • 1.2.4. Estimates and forecasts timeline.
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Cancer outlook
    • 2.2.2. Technology outlook
    • 2.2.3. Test Type outlook
    • 2.2.4. End Use outlook
    • 2.2.5. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Hereditary Cancer Testing Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Technological advancements of genetic testing in cancer detection
      • 3.2.1.2. Integration with precision medicine
      • 3.2.1.3. Growing awareness through public and government initiatives
      • 3.2.1.4. Rising prevalence of cancer
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High costs and limited insurance coverage
  • 3.3. U.S. Hereditary Cancer Testing Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTEL Analysis

Chapter 4. U.S. Hereditary Cancer Testing Market: Cancer Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. U.S. Hereditary Cancer Testing Market: Cancer Movement Analysis
  • 4.3. U.S. Hereditary Cancer Testing Market Size & Trend Analysis, by cancer, 2021 to 2033 (USD Million)
  • 4.4. U.S. Hereditary Cancer Testing Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5. Lung Cancer
    • 4.5.1. Lung Cancer Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.6. Breast Cancer
    • 4.6.1. Breast Cancer Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.7. Colorectal Cancer
    • 4.7.1. Colorectal Cancer Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.8. Cervical Cancer
    • 4.8.1. Cervical Cancer Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.9. Ovarian Cancer
    • 4.9.1. Ovarian Cancer Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.10. Prostate Cancer
    • 4.10.1. Prostate Cancer Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.11. Stomach/Gastric Cancer
    • 4.11.1. Stomach/Gastric Cancer Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.12. Melanoma
    • 4.12.1. Melanoma Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.13. Sarcoma
    • 4.13.1. Sarcoma Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.14. Uterine Cancer
    • 4.14.1. Uterine Cancer Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.15. Pancreatic Cancer
    • 4.15.1. Pancreatic Cancer Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.16. Others
    • 4.16.1. Others Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. U.S. Hereditary Cancer Testing Market: Technology Estimates & Trend Analysis

  • 5.1. Technology Market Share, 2024 & 2033
  • 5.2. Segment Dashboard
  • 5.3. U.S. Hereditary Cancer Testing Market by Technology Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 5.5. Cytogenetic
    • 5.5.1. Cytogenetic Market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.6. Biochemical
    • 5.6.1. Biochemical Market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.7. Molecular Testing
    • 5.7.1. Molecular Testing Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. U.S. Hereditary Cancer Testing Market: Test Type Estimates & Trend Analysis

  • 6.1. Test type Market Share, 2024 & 2033
  • 6.2. Segment Dashboard
  • 6.3. Test type Market by Capacity Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 6.5. Predictive Testing
    • 6.5.1. Predictive Testing Market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.6. Diagnostic Testing
    • 6.6.1. Diagnostic Testing Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. U.S. Hereditary Cancer Testing Market: End Use Estimates & Trend Analysis

  • 7.1. End Use Market Share, 2024 & 2033
  • 7.2. Segment Dashboard
  • 7.3. End Use Market by End Use Outlook
  • 7.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 7.5. Diagnostic Centers
    • 7.5.1. Diagnostic Centers Market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6. Hospitals
    • 7.6.1. Hospitals Market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7. Clinics
    • 7.7.1. Clinics Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. List of key distributors and channel partners
    • 8.3.2. Key customers
    • 8.3.3. Key company market share analysis, 2024
    • 8.3.4. Myriad Genetics, Inc.
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Services benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. Invitae Corporation
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Services benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. Bio-Rad Laboratories
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Services benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. CSL Ltd
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Services benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. Qiagen NV
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Services benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. Danaher Corporation
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Services benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. Thermo Fisher Scientific
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Services benchmarking
      • 8.3.10.4. Strategic initiatives
    • 8.3.11. Abbott Laboratories
      • 8.3.11.1. Company overview
      • 8.3.11.2. Financial performance
      • 8.3.11.3. Services benchmarking
      • 8.3.11.4. Strategic initiatives
    • 8.3.12. EUROFINS SCIENTIFIC
      • 8.3.12.1. Company overview
      • 8.3.12.2. Financial performance
      • 8.3.12.3. Services benchmarking
      • 8.3.12.4. Strategic initiatives
    • 8.3.13. F. HOFFMANN-LA ROCHE LTD
      • 8.3.13.1. Company overview
      • 8.3.13.2. Financial performance
      • 8.3.13.3. Services benchmarking
      • 8.3.13.4. Strategic initiatives
    • 8.3.14. Illumina, Inc.
      • 8.3.14.1. Company overview
      • 8.3.14.2. Financial performance
      • 8.3.14.3. Services benchmarking
      • 8.3.14.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 U.S Hereditary cancer testing market, by cancer, 2021 - 2033 (USD Million)
  • Table 3 U.S Hereditary cancer testing market, by technology, 2021 - 2033 (USD Million)
  • Table 4 U.S Hereditary cancer testing market, by test type, 2021 - 2033 (USD Million)
  • Table 5 U.S Hereditary cancer testing market, by end user, 2021 - 2033 (USD Million)

List of Figures

  • Fig.1 Market research process
  • Fig.2 Data triangulation techniques
  • Fig.3 Primary research pattern
  • Fig.4 Primary interviews in North America
  • Fig.5 Primary interviews in Europe
  • Fig.6 Primary interviews in APAC
  • Fig.7 Primary interviews in Latin America
  • Fig.8 Primary interviews in MEA
  • Fig.9 Market research approaches
  • Fig.10 Value-chain-based sizing & forecasting
  • Fig.11 QFD modeling for market share assessment
  • Fig.12 Market formulation & validation
  • Fig.13 Hereditary cancer testing market: market outlook
  • Fig.14 Hereditary cancer testing competitive insights
  • Fig.15 Parent market outlook
  • Fig.16 Related/ancillary market outlook
  • Fig.17 Penetration and growth prospect mapping
  • Fig.18 Industry value chain analysis
  • Fig.19 Hereditary cancer testing market driver impact
  • Fig.20 Hereditary cancer testing market restraint impact
  • Fig.21 Hereditary cancer testing market strategic initiatives analysis
  • Fig.22 Hereditary cancer testing market: Cancer movement analysis
  • Fig.23 Hereditary cancer testing market: Cancer outlook and key takeaways
  • Fig.24 Hereditary cancer Testing market estimates and forecast, 2021 - 2033
  • Fig.25 Hereditary cancer testing Market: Technology movement analysis
  • Fig.26 Hereditary cancer testing market: Technology outlook and key takeaways
  • Fig.27 Cytogenetic market estimates and forecasts, 2021 - 2033
  • Fig.28 Biochemical market estimates and forecasts,2021 - 2033
  • Fig.29 Molecular Testing market estimates and forecasts,2021 - 2033
  • Fig.30 Hereditary cancer testing Market: Test Type movement analysis
  • Fig.31 Hereditary cancer testing Market: Test Type outlook and key takeaways
  • Fig.32 Predictive Testing market estimates and forecasts, 2021 - 2033
  • Fig.33 Diagnostic Testing market estimates and forecasts, 2021 - 2033
  • Fig.34 Hereditary cancer testing Market: End Use movement analysis
  • Fig.35 Hereditary cancer testing market: End Use outlook and key takeaways
  • Fig.36 Diagnostic Centers market estimates and forecasts, 2021 - 2033
  • Fig.37 Hospitals market estimates and forecasts, 2021 - 2033
  • Fig.38 Clinics market estimates and forecasts, 2021 - 2033
  • Fig.39 Market share of key market players- Hereditary cancer testing market